Search
Citalopram
go.drugbank.com/drugs/DB00215ApprovedInvestigationalIt is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. … [A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors.
Mixtures: Sentralopram AM-10Categories: Monoamine Oxidase A Substrates, Cytochrome P-450 SubstratesBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigationalBrolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet, Pagenax 120mg/ml Solution For InjectionKetotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigationalIt has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine]. … Ketotifen is a benzocycloheptathiophene derivative[A231204] with potent antihistaminic and mast cell stabilizing properties.
Products: FUMAST 1 MG/5 ML SURUP, 100 ML, MITOFEN 1 MG/5 ML SURUP 100 MLAcarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigationalAcarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines.
Products: GLUCOBAY 100 TABLET 100 mg, ACARBOSA 100 MGOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.
Mixtures: Olmesartan/Amlodipin 1A Pharma 40 mg/10 mg - Filmtabletten, ILTUXAM ® 20 MG - 10 MGProducts: OLMESARTAN AL 10 MG FTA, OLMESARTAN AL 20 MG FTABrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalBrigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesProducts: VIGIA® 100 MG, CARIM 100 MGCyclophosphamide
go.drugbank.com/drugs/DB00531ApprovedInvestigationalPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, a...
Categories: Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexProducts: CICLOFOSFAMIDA 200 MG POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE., ENDOXAN 50 MG KAPLI TABLET, 50 ADETEtomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalImidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
Products: ETOMIDATE-LIPURO INJECTION 20 mg/10 ml, HYPNOMIDATE 2 MG /10 ML AMPUL, 5 ADETHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.
Mixtures: TRI NORMIN 50Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors